NOW FDA APPROVED

See our press release

© 2025 Abeona Therapeutics Inc. All rights reserved. US-COM-ZEV-250033 03/25

Contact Us Careers
Facebook Twitter LinkedIn
logo_abeona_retina
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers
×
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers

Press Releases

Investors

Investors & Media

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Scientific Advisory Board
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts

Abeona Therapeutics Announces Public Offering of Common Stock

Oct 16, 2017

Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies

Oct 16, 2017

Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA

Oct 11, 2017

Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa

Oct 6, 2017

Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio

Oct 4, 2017

Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102

Sep 28, 2017

Abeona Therapeutics Announces Upcoming Conference Participation

Sep 22, 2017

Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa

Aug 29, 2017

Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017

Aug 17, 2017

Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights

Aug 15, 2017
RSS
    • 1...
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • ...31

    © 2025 Abeona Therapeutics Inc. All Rights Reserved. | Privacy Policy Terms of Use